Sex steroids and schizophrenia

Area of Science:

• Neuroscience
• Psychiatry
• Endocrinology

Background:

• Schizophrenia incidence shows distinct sex-based patterns, peaking in late adolescence, earlier and more steeply in males.
• Women experience a secondary incidence peak post-menopause, suggesting a potential protective role for ovarian hormones.
• Men have a significantly higher overall risk (approx. 40%) of developing schizophrenia compared to women.

Purpose of the Study:

• To explore the under-investigated role of testosterone in schizophrenia.
• To examine the influence of gonadal steroids on schizophrenia vulnerability, particularly during adolescence.
• To leverage preclinical models to understand sex differences in neurodevelopmental insults relevant to schizophrenia.

Main Methods:

• Review of existing meta-analyses on schizophrenia incidence and sex differences.
• Analysis of findings related to gonadal hormone levels in individuals with schizophrenia.
• Examination of preclinical research on sex differences in neurodevelopmental insults.

Main Results:

• Male vulnerability to schizophrenia is greater than female vulnerability.
• Ovarian hormones are hypothesized to be protective against schizophrenia.
• Testosterone's role in schizophrenia remains less understood, despite reported disruptions in men with the illness.

Conclusions:

• Gonadal steroids significantly impact brain development and function, influencing psychiatric illness risk.
• Adolescent hormonal changes and their interplay with social/biological factors complicate clinical studies of schizophrenia.
• Preclinical models indicate greater male vulnerability to neurodevelopmental insults, offering insights into gonadal steroid roles in psychiatric disorders.